AZ Joins Spin-Out Set, Forms GI Play Albireo
This article was originally published in Start Up
Executive Summary
AstraZeneca has completed its first ever biotech spin out, creating the Swedish biotech firm Albireo with backing led by Nomura Phase4 Ventures. The deal underscores pharma's disenchantment with certain aspects of GI drug development and may blaze a trail for other non-core areas of R&D at the drugmaker.
You may also be interested in...
NASH Companies Take The Stage At AASLD
NGM’s injectable might be best-suited as induction therapy for sicker NASH patients, Inventiva hopes its pan-PPAR agonist will outperform Genfit’s elafibranor, and Albireo thinks IBAT inhibition offers promise in NASH.
Albireo Making Headway In Rare Pediatric Liver Diseases With IBAT Inhibition
Biotech hopes to launch a Phase III trial in the rare disorder PFIC before year’s end. It thinks its therapy could offer similar benefits to surgery in reducing pruritus and improving liver parameters.
AZ Spins Out Entasis To Tackle Resistant Infections
AstraZeneca has, after a long gestation, given birth to the antibiotic developer Entasis Therapeutics: in early July the biotech debuted with $40 million in funding from AZ alone, and a portfolio of the drugmaker’s early-stage antibiotic candidates. It emerges as the debate about incentivizing antibiotics R&D intensifies amid growing concerns about antibiotic-resistant bacteria.